The Future of NDMM: Ongoing Studies and Current Challenges in the Landscape
Melissa Alsina, MD cites recent data from ongoing studies as well as highlights remaining questions and unmet needs in the NDMM landscape.
Toxicity Management in Patients with Transplant-Not Preferred NDMM
An overview of prominent toxicities observed in patients receiving treatment for NDMM and standard countermeasures to address them, with a focus on neuropathy.
Insights Concerning the Use of VRd versus Rd in Patients with NDMM
Dr Alsina describes key findings from the post-hoc analysis of the SWOG S0777 trial and explains how they inform treatment strategies for elderly patients.
MAIA Trial: D-Rd for Transplant-Not Preferred NDMM
A subject-matter-expert reviews updated efficacy results and subgroup analyses from the MAIA trial, evaluating D-Rd for transplant-not preferred NDMM.
Diagnosing and Assessing Treatment Options for Patients with Transplant-Not Preferred NDMM
Dr Alsina outlines criteria used in determining transplant eligibility and her approach to assessing standard risk versus high-risk in patients with NDMM.
A 77-Year-Old Man with Transplant-Not Preferred Newly Diagnosed Multiple Myeloma (NDMM)
Melissa Alsina, MD introduces a newly diagnosed multiple myeloma patient case, providing her perspective on the patient’s prognosis and treatment.
2 Commerce Drive Cranbury, NJ 08512